NPCE
Neuropace Inc
NASDAQ: NPCE · HEALTHCARE · MEDICAL DEVICES
$16.86
+1.93% today
Updated 2026-04-30
Market cap
$585.64M
P/E ratio
—
P/S ratio
5.86x
EPS (TTM)
$-0.66
Dividend yield
—
52W range
$8 – $19
Volume
0.2M
Neuropace Inc (NPCE) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $36.97M | $41.14M | $45.18M | $45.52M | $65.42M | $79.91M | $99.99M |
| Revenue growth (YoY) | — | +11.3% | +9.8% | +0.7% | +43.7% | +22.1% | +25.1% |
| Cost of revenue | $10.51M | $10.87M | $11.75M | $13.03M | $17.30M | $20.82M | $22.77M |
| Gross profit | $26.46M | $30.27M | $33.44M | $32.49M | $48.12M | $59.09M | $77.22M |
| Gross margin | 71.6% | 73.6% | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% |
| R&D | $18.29M | $15.70M | $18.21M | $21.95M | $20.78M | $23.65M | $27.89M |
| SG&A | $30.20M | $27.63M | $38.96M | $51.34M | $54.52M | $57.10M | $19.09M |
| Operating income | $-22.03M | $-13.05M | $-23.74M | $-40.79M | $-27.17M | $-21.67M | $-16.34M |
| Operating margin | -59.6% | -31.7% | -52.5% | -89.6% | -41.5% | -27.1% | -16.3% |
| EBITDA | $-20.07M | $-12.48M | $-28.37M | $-36.57M | $-22.83M | $-16.57M | $-14.39M |
| EBITDA margin | -54.3% | -30.3% | -62.8% | -80.3% | -34.9% | -20.7% | -14.4% |
| EBIT | $-20.49M | $-12.79M | $-28.67M | $-39.55M | $-24.44M | $-18.34M | $-16.34M |
| Interest expense | $9.48M | $11.49M | $7.41M | $7.53M | $8.52M | $8.80M | $7.46M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-29.97M | $-24.28M | $-36.08M | $-47.08M | $-32.96M | $-27.14M | $-21.46M |
| Net income growth (YoY) | — | +19.0% | -48.6% | -30.5% | +30.0% | +17.6% | +20.9% |
| Profit margin | -81.1% | -59.0% | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |